Korro Bio (KRRO) AI Stock Analysis

• Market Cap: $184.61M
• Dividend Yield: N/A
• Average Volume (3M): 734.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.52
• Revenue Growth: N/A
• EPS Growth: 21.61%
• Country: US
• Employees: 112
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -5.33
• Shares Outstanding: 9,417,295
• 10 Day Avg. Volume: 1,808,258
• 30 Day Avg. Volume: 734,659
• PEG Ratio: -0.02
• Price to Book (P/B): 1.46
• Price to Sales (P/S): 11.77
• P/FCF Ratio: -0.95
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 22.25
• Enterprise Value/Gross Profit: 27.88
• Enterprise Value/Ebitda: -1.21
• 1Y Price Target: $18.83
• Price Target Upside: 63.77% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): -8.05
• Revenue Forecast (FY): $2.20M

• Rating: 47 Neutral
• Price Target: $12.50 ▲(8.70% Upside)
• Action: Reiterated Date: 03/14/26
• Date: Action: Reiterated 03/14/26

The score is held down primarily by weak financial performance—large losses, significant ongoing cash burn, and a weakening balance sheet. Technicals provide a modest offset with improving short-term momentum, while valuation is constrained by a negative P/E and lack of dividend support. Corporate events are a net positive due to the sizable PIPE financing extending runway, but pipeline/trial termination risk tempers the benefit.

Positive Factors

Extended funding runway via $85M PIPE

The oversubscribed $85M PIPE materially extends operational runway into H2 2028, reducing near-term financing risk and enabling the company to fund multiple clinical programs to key data inflection points. This durable financing horizon improves execution optionality and lowers immediate dilution pressure while teams advance value-driving milestones.

Proprietary OPERA RNA‑editing platform

Korro’s OPERA oligonucleotide RNA-editing platform represents a structural competitive advantage: platform technologies allow multiple programs from shared chemistry and insight. A scalable, differentiated modality can produce repeatable value creation across diseases, attract partnerships, and sustain long-term pipeline growth independent of any single asset.

KRRO-121 progress toward filing

Progress toward a regulatory filing for KRRO-121 in H2 2026 is a structural de-risking catalyst: moving an RNA‑editing candidate into first‑in‑human trials could validate modality, unlock partnering and milestone streams, and establish a clinical development pathway for addressing urea cycle disorders and related liver indications.

Negative Factors

Persistent high cash burn

Consistent, large negative operating and free cash flow (worsening to ~-$79M in 2025) creates an ongoing financing imperative. Over months to years this persistent burn increases dilution risk, constrains strategic flexibility, and forces management to prioritize near-term program funding over broader, longer‑term R&D investments if additional capital is required.

Weakened balance sheet and rising leverage

Sharp erosion of equity alongside rising leverage reduces financial resilience: higher debt-to-equity (~0.85) and compressed shareholder equity limit the firm’s capacity to absorb clinical setbacks or invest opportunistically. This structural weakening increases vulnerability to adverse outcomes and may raise future financing costs or terms.

Program and collaboration setbacks

Termination of the KRRO-110 trial and a 12‑month pause with a major partner are durable red flags: they reduce near-term data flow and partnership validation, concentrate risk on fewer assets, and may delay development timelines. Such setbacks can materially alter strategic plans and increase the importance of successful execution on remaining programs.

Korro Bio Business Overview & Revenue Model

Company Description

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

How the Company Makes Money

As a clinical-stage biotechnology company, Korro Bio does not have publicly established, recurring product revenue from commercialized therapies. Its revenue, when present, is primarily expected to come from (i) collaboration and partnership arrangements (such as upfront payments, research funding, option fees, and milestone payments tied to development, regulatory, or commercial events) and (ii) potential future royalties on net sales if partnered products reach commercialization. If there are periods without active collaboration revenue, the company typically funds operations through financing activities (e.g., equity offerings), which are not operating revenue. Specific counterparties, deal terms, and the magnitude/timing of any collaboration or milestone revenue are null if not disclosed in the referenced period.

Korro Bio Financial Statement Overview

Summary

Financials reflect a high-burn biotech profile: revenue is volatile and recently down (~13% in 2025 vs. 2024) with large and widening losses. Cash flow is a key weakness with persistently negative operating and free cash flow and worsening operating cash outflow in 2025. The balance sheet is weakening as equity compressed sharply and leverage rose, though equity remains positive.

Income Statement

Revenue is volatile and has trended down recently (2025 revenue down ~13% vs. 2024), following a sharp drop from 2021 to 2023 (including periods of near-zero revenue). Profitability remains very weak with large operating and net losses each year, and TTM (Trailing-Twelve-Months) profitability is not provided. The main positive is that revenue did rebound in 2024–2025 versus 2023, but losses expanded meaningfully in 2025, keeping the earnings profile highly pressured.

Balance Sheet

Leverage is moderate in the most recent year (2025 debt-to-equity ~0.85), but it has increased sharply versus 2023–2024 when leverage was low (~0.20–0.28). Equity remains positive in 2025 (~$51M), yet it fell substantially from 2024 (~$160M), reflecting ongoing losses and/or balance sheet changes. Total debt is relatively stable (~$33M–$45M in most years, excluding 2022), but returns on equity are deeply negative in 2024–2025, highlighting erosion of shareholder value despite an overall asset base that is still meaningful.

Cash Flow

Cash generation is consistently negative: operating cash flow and free cash flow are materially negative every year, with 2025 operating cash flow deteriorating to about -$79M versus -$60M in 2024. Free cash flow remains deeply negative (roughly -$75M to -$79M in 2023–2025), indicating continued cash burn typical of an R&D-heavy biotech. A modest positive is that free cash flow improved in 2025 versus 2024 (positive growth), but the overall funding need remains high given persistent and sizeable outflows.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.39M	2.27M	0.00	0.00	14.07M
Gross Profit	0.00	2.27M	0.00	0.00	10.23M
EBITDA	-121.86M	-88.34M	-80.90M	-56.49M	-80.07M
Net Income	-117.26M	-83.58M	-81.17M	-58.03M	-84.69M
Balance Sheet
Total Assets	113.51M	226.24M	221.66M	73.74M	185.36M
Cash, Cash Equivalents and Short-Term Investments	75.16M	126.09M	166.15M	55.85M	130.71M
Total Debt	43.49M	44.77M	33.21M	166.99M	45.60M
Total Liabilities	62.07M	65.83M	51.75M	172.77M	54.53M
Stockholders Equity	51.44M	160.41M	169.91M	-99.03M	130.82M
Cash Flow
Free Cash Flow	-79.08M	-77.98M	-75.12M	-58.86M	-36.54M
Operating Cash Flow	-78.56M	-60.07M	-67.28M	-53.65M	-32.09M
Investing Cash Flow	43.99M	-123.35M	11.16M	11.06M	-39.50M
Financing Cash Flow	685.00K	69.36M	187.76M	18.00K	115.94M

Korro Bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.50
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRRO, the sentiment is Positive. The current price of 11.5 is below the 20-day moving average (MA) of 11.58, above the 50-day MA of 10.91, and below the 200-day MA of 18.74, indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 59.43 is Neutral, neither overbought nor oversold. The STOCH value of 40.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KRRO.

Korro Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANNX	56 Neutral	$819.17M	-2.07	-92.28%	―	―	-35.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DSGN	51 Neutral	$624.12M	-7.71	-29.83%	―	―	-40.26%
ASMB	49 Neutral	$444.70M	-5.33	-59.01%	―	31.30%	32.79%
KRRO	47 Neutral	$184.61M	-0.64	-63.46%	―	―	21.61%
FDMT	47 Neutral	$424.90M	-2.14	-47.27%	―	―	―
AURA	42 Neutral	$377.21M	-3.90	-69.67%	―	―	-11.41%

Korro Bio Corporate Events

Korro Bio Announces Oversubscribed $85M PIPE Financing

On March 9, 2026, Korro Bio entered into a subscription agreement for an oversubscribed private investment in public equity, selling common shares and pre-funded warrants to institutional investors for expected gross proceeds of about $85 million, with closing targeted for March 10, 2026. Led by Venrock Healthcare Capital Partners with participation from several new and existing healthcare-focused funds, the financing underscores investor confidence in Korro’s RNA editing platform and expands its access to non-dilutive public markets alternatives.

Korro said the new capital, combined with $85.2 million in cash and equivalents at year-end 2025, should extend its funding runway into the second half of 2028 and support clinical milestones across multiple programs, including KRRO-121 for hyperammonemia in urea cycle disorders and a GalNAc-conjugated candidate for alpha-1 antitrypsin deficiency. The raise also funds advancement of a longevity and liver health program targeting the AMPKγ1 pathway and is accompanied by a registration rights agreement giving investors resale registration for the new securities, aligning capital structure flexibility with the company’s push toward value-inflecting clinical data.

The most recent analyst rating on (KRRO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.

Korro Bio Showcases KRRO-121 RNA Editing Program Progress

On January 27, 2026, Korro Bio, Inc. held a virtual Analyst Day where management presented KRRO-121, a GalNAc-conjugated antisense oligonucleotide designed to edit glutamine synthetase (GS) mRNA in the liver, creating a more stable GS variant to enhance ammonia clearance. The company highlighted preclinical data showing that KRRO-121 stabilized GS and improved ammonia control in human cell models of urea cycle disorders, underscoring its potential as a first-in-class, pan-urea cycle disorder treatment that could relax dietary restrictions and address broader ammonia-driven conditions such as hepatic encephalopathy; Korro also indicated plans to submit a regulatory filing in the second half of 2026 to enable a first-in-human trial, marking a key step in advancing its RNA-editing platform and expanding its presence in the genetic medicines space.

The most recent analyst rating on (KRRO) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.

Korro Bio Updates Pipeline, Terminates KRRO-110 REWRITE Trial

On January 15, 2026, Korro Bio, Inc. updated its corporate presentation for investors and analysts, outlining a pipeline that includes KRRO-121 for hyperammonemia progressing toward a planned regulatory filing in the second half of 2026, an AATD GalNAc-conjugated development candidate expected to be nominated in the first half of 2026, and a liver-focused longevity program and TDP43-targeted ALS program that leverage RNA-editing approaches. The company disclosed it has terminated the REWRITE clinical trial for KRRO-110 in AATD and that its collaboration with Novo Nordisk entered a 12‑month pause in November 2025, signaling a strategic pivot toward newer RNA-editing assets that may reshape its near-term development priorities and investor focus.

The most recent analyst rating on (KRRO) stock is a Sell with a $8.50 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.

Korro Bio Enhances Executive Compensation and Retention Incentives

On December 15, 2025, Korro Bio, Inc. amended and restated the employment agreement of executive Jeffrey Cerio, keeping most terms consistent with his August 28, 2024 contract but raising his annual base salary to $425,000 and enhancing his severance protections, including longer payout periods in the event of termination without cause or resignation for good reason, particularly following a change in control. As part of a broader employee appreciation and retention effort, Korro also granted Cerio a $100,000 cash bonus, payable in two tranches in late 2025 and mid-2026 contingent on continued service, and awarded him 41,902 restricted stock units vesting in mid-2026 and late 2026, underscoring the company’s focus on retaining key leadership through more robust cash and equity incentives.

The most recent analyst rating on (KRRO) stock is a Hold with a $81.00 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.